The HLA-B*5801 allele has been shown to be associated with the risk of developing allopurinol related hypersensitivity syndrome, and if the patient is a known carrier of HLA-B*5801 allopurinol should not be started unless there are no other reasonable therapeutic options and the benefits are thought to exceed risks.
The recommendation to screen in high prevalence subgroups is new.